Opsoclonus-myoclonus …

David T Hsieh MD

Neuro-Oncology

Updated 12.27.2023
Released 03.14.1994
Expires For CME 12.27.2026

Opsoclonus-myoclonus

Author: David T Hsieh MD

See Contributor Disclosures

Editor: Bernard L Maria MD

Opsoclonus-myoclonus

In This Article

Quick Link

Introduction

Overview

Opsoclonus-myoclonus syndrome is a presumed autoimmune-mediated syndrome characterized by acute or subacute onset of abnormal eye movements, myoclonic jerks, ataxia, dysarthria, and behavioral changes in the setting of B-cell expansion within the cerebrospinal fluid. The etiology is most often paraneoplastic, especially neuroblastoma in children and oat cell, squamous cell, or adenocarcinoma in adults, but the etiology may also be parainfectious. After treatment for the underlying etiology, if known, medical management of neurologic symptoms usually involves immunomodulation. The long-term prognosis for many children includes some persistence of behavioral or cognitive difficulties. The International OMS Study Group has published recommendations for the diagnosis and management of opsoclonus-myoclonus syndrome, and an international pediatric-onset opsoclonus-myoclonus ataxia syndrome registry has been organized.

Key points

	• Opsoclonus-myoclonus syndrome is a presumed autoimmune-mediated syndrome characterized by acute or subacute onset of abnormal eye movements, myoclonic jerks, ataxia, dysarthria, and behavioral changes in the setting of B-cell expansion within the cerebrospinal fluid.
	• The etiology is most often paraneoplastic, especially neuroblastoma in children and oat cell, squamous cell, or adenocarcinoma in adults, but the etiology may also be parainfectious.
	• After surgical or medical management of the underlying etiology, if known, medical management of neurologic symptoms usually involves immunomodulation, most commonly involving ACTH, corticosteroids, or IVIg, but with an emerging use of rituximab, a monoclonal anti-B-cell antibody.
	• The long-term prognosis for many children includes some persistence of behavioral or cognitive difficulties.

Historical note and terminology

The term "opsoclonus" was first used by Orzechowski in 1913 to describe rapid, chaotic, but conjugate, eye movements. It is derived from the Greek for vision (opsis) and turmoil (klonos). In 1927, Orzechowski reported the association of opsoclonus with myoclonus. However, it was not until later, following Kinsbourne's classic description of myoclonic encephalopathy in infants (50), that opsoclonus-myoclonus syndrome was associated with neuroblastoma (102; 57; 99; 10; 14). This syndrome has been given a variety of names, underscoring the difficulty in summarizing variable symptoms of opsoclonus, myoclonus, ataxia, and encephalopathy. Although "infantile myoclonic encephalopathy" and “dancing eyes-dancing feet” syndrome are terms that endure, "opsoclonus-myoclonus syndrome" or “opsoclonus-myoclonus ataxia syndrome” better reflect current usage.

Clinical manifestations

Presentation and course

	• Opsoclonus-myoclonus syndrome is characterized by abnormal eye movements, myoclonus, ataxia, and behavioral changes.
	• Cognitive and behavioral changes vary in severity, although irritability is usually present at the outset.

Opsoclonus-myoclonus syndrome is characterized by acute or subacute onset of abnormal eye movements, myoclonic jerks, ataxia, dysarthria, and behavioral change. Considerable variation in severity and predominance of symptoms is seen among affected children. Opsoclonus, for example, may be overlooked in cases with severe ataxia. In addition, opsoclonus may begin after onset of ataxia or myoclonus (21; 96). This variability contributes to the commonly occurring delay in the diagnosis of opsoclonus-myoclonus syndrome, with an average time to diagnosis of 1.2 months and average time to treatment of 1.4 months (81). Opsoclonus is characterized by random, fragmentary, conjugate saccades that may occur in any direction. It is present with eyes open or closed, increasing during saccades and persisting during REM sleep (34). The abnormal movements occur less frequently during visual fixation, but they nevertheless disrupt purposeful gaze.

Opsoclonus

This 16-year-old girl shows chaotic eye movements suggestive of opsoclonus. The girl recovered from Japanese encephalitis. (Contributed by Dr. Ravindra Kumar Garg.)

Myoclonus in opsoclonus-myoclonus syndrome is characterized by generalized jerks, predominantly involving proximal muscles, which continue with decreased amplitude during REM sleep. Axial and abdominal muscles are commonly involved. Myoclonic jerks may range in severity from mild to violent, but they tend to be arrhythmic and independent of external stimuli. It is often difficult to distinguish axial myoclonus from ataxia (28), both of which may compromise crawling, standing, or walking despite preservation of normal strength (50; 22).

Opsoclonus-myoclonus

The patient is a 2.5-year-old girl who developed opsoclonus, myoclonus, and ataxia after an illness characterized by high fever and ulcerations of oral mucosa. She was treated with adrenocorticotrophic hormone (ACTH) for five days...

Pointing and reaching are also compromised by proximal myoclonus and dysmetria. In severe cases the child may lose his ability to play with toys or feed himself. Titubation of the head often accompanies truncal ataxia. Children typically become so frustrated by their loss of functional vision and muscle control that they may refuse to leave their parent's arms. In severe cases, hyperreflexia, clonus, and abnormal plantar responses are seen. In mild or resolving cases, motor symptoms may be limited to slowing of rapid alternating movements.

Although facial muscles of children with opsoclonus-myoclonus syndrome are uncommonly affected by myoclonus, some children show mild facial diplegia, characterized by a gaping mouth with increased drooling and decreased smiling. Speech is often dysarthric, and many children become unwilling or unable to talk (50; 22; 99).

Cognitive and behavioral changes also vary in severity, although irritability is usually present at the outset. Inattentiveness, hyperactivity, and aggressive behavior are often seen in opsoclonus-myoclonus syndrome. Deficits in intellectual function may accompany or follow the onset of motor symptoms (28; 14). Atypical sensory behaviors such as anxiety and a greater sensitivity to auditory stimuli are also reported (35).

Prognosis and complications

Approximately 60% of children with paraneoplastic opsoclonus-myoclonus ataxia will experience resolution of symptoms, usually over several months (94). There is speculation that chemotherapy for neuroblastoma may improve neurologic outcome; surgical removal of tumor does not always cause symptoms to diminish. Prognosis for normal neurologic function following opsoclonus-myoclonus syndrome is not good (106; 61). Two thirds of children with paraneoplastic opsoclonus-myoclonus ataxia have persistent deficits including speech delay, cognitive impairment, motor delay, and behavioral problems (94). Following childhood opsoclonus-myoclonus syndrome, intellectual disability is present in 24%, with another 22% persisting with milder learning impairments (101). The number of relapses negatively correlated with full scale IQ in this large international cohort study (101). A rapid response to ACTH without subsequent relapses foreshadows a better prognosis (40). Severe initial symptoms or a younger age are risk factors for developing long-term neurologic sequelae (16). Correlation has been identified between cerebellar grey matter loss identified by MR imaging and more persistent, severe symptomatology (03).

Outcome in children with neuroblastoma is related to amplification of the N-myc oncogene. Patients with more than 10 amplifications of the N-myc DNA sequence have a poor prognosis, even if neuroblastoma is diagnosed in infancy (109). Children presenting with opsoclonus-myoclonus syndrome and neuroblastoma typically have single copies of the N-myc sequence (23), accounting for long-term survival in 80% to 90% of this group of children (02; 46). Additionally, the discovery that IgG preparations of patients with opsoclonus-myoclonus syndrome, which in vitro reduce the proliferation of neuroblastoma cells, may also account for the less aggressive nature of this subset of patients with neuroblastoma (13).

Symptoms of opsoclonus-myoclonus syndrome may improve spontaneously with resection of a neural crest tumor; however, in most cases ACTH or steroid treatment is required to minimize symptoms and prevent relapse (61). Following resection, recurrent episodes of ataxia may occur, but neurodevelopmental delay and persistent behavioral problems are more common factors in assessing long-term outcome (106; 53). Of all of the behavioral symptoms of opsoclonus-myoclonus syndrome (cognitive impairment, attention deficit disorder [ADD], and obsessive-compulsive disorder), sleep disturbance and rage attacks are reported to be most problematic to families (104). Trazodone may be of benefit in this situation (78).

Outcome in adults is dependent on whether opsoclonus-myoclonus is idiopathic or paraneoplastic in origin, with a more severe course in paraneoplastic opsoclonus-myoclonus and a more benign course in idiopathic or parainfectious opsoclonus-myoclonus (08; 52). Idiopathic opsoclonus-myoclonus tends to respond well to immunotherapy with a monophasic course that results in either mild truncal ataxia or complete resolution of symptoms. Paraneoplastic opsoclonus-myoclonus treatment with immunotherapy infrequently has complete recovery before the tumor is treated. With tumor treatment, most have residual mild truncal ataxia.

Clinical vignette

A previously healthy 7-year-old girl presented with “funny eye movements” after two weeks of vaguely described intermittent irritability. On examination, her eye movements consisted of intermittent, chaotic, conjugate, quick movements in all directions. At times these eye movements subsided, especially with gaze fixation. She was irritable at times, but was usually consolable by her parents. Brain MRI and basic laboratory studies to include CSF studies were normal. No definite masses in the chest, abdomen, or pelvis were seen with CT scan. During the evaluation, there was subsequent development of subtle upper extremity myoclonic jerks. A metaiodobenzylguanidine (MIBG) scan was performed, and a tiny, right paravertebral area of increased uptake was noted. Surgical resection revealed a lesion with the histology of stage 1 neuroblastoma. Postoperatively, the opsoclonus and myoclonus mostly subsided, but the irritability persisted. The patient was initiated on a course of ACTH, with good short-term resolution of her symptoms.

Biological basis

Etiology and pathogenesis

	• In children, the two major triggers of opsoclonus-myoclonus syndrome are neural crest tumors and viral infection.
	• In adults, in addition to parainfectious causes, opsoclonus-myoclonus syndrome occurs as a paraneoplastic phenomenon with oat cell carcinoma, adenocarcinoma, and squamous cell carcinoma.
	• Opsoclonus-myoclonus syndrome is most likely an autoimmune disorder with immunologic cross-reactivity between neuroblastoma cells and selected neurons, with production of antineuronal antibodies. Alternatively, an infecting virus, through molecular mimicry, may stimulate the production of autoantibodies.

The underlying mechanism of neuronal injury causing opsoclonus-myoclonus syndrome is unknown. However, the two major triggers of opsoclonus-myoclonus syndrome in children are neural crest tumors and viral infection. Whether the etiology is tumor or parainfectious, however, clinical presentation is not distinguishable between the two etiologies (82). Neuroblastoma is the most common tumor, occurring most often in the mediastinum in children with opsoclonus-myoclonus syndrome (99; 14). Less common extracranial sites include retroperitoneal, adrenal, sacrococcygeal, or superior cervical ganglion locations. Ganglioneuroblastoma and ganglioneuroma are other neural crest tumors associated with opsoclonus-myoclonus syndrome.

Numerous agents have been reported to cause infections that precede opsoclonus-myoclonus syndrome (73). These include Epstein-Barr virus, Coxsackie B3 (55), Herpes zoster, lymphocytic choriomeningitis, mumps (45), rubella, Lyme disease (68), group A Streptococcus (47), Salmonellosis (33), Mycoplasma pneumoniae (43), cytomegalovirus (112), hepatitis C (30), rotavirus (36), and possibly West Nile Virus (49). It has also been reported that HIV seroconversion can have opsoclonus-myoclonus as the presenting symptom (06; 52). Opsoclonus-myoclonus has been reported in association with coronavirus disease 19 (COVID-19) (100; 29). Rarely, this disorder has followed immunization; it was noted to have manifested after an initial human papilloma virus vaccination, with a sharp progression in severity on receipt of the second dose booster (60). A report also adds Aicardi-Goutieres syndrome (ACS) to the differential diagnosis in children (01). Aicardi-Goutieres syndrome is a rare genetically inherited neuroinflammatory disorder presenting with encephalopathic and inflammatory symptoms due to abnormal upregulation of type 1 interferon signaling. A case series of three children with Aicardi-Goutieres syndrome reported transient opsoclonus and myoclonus after a period of irritability and/or developmental regression.

In adults, in addition to parainfectious causes, opsoclonus-myoclonus syndrome occurs as a paraneoplastic phenomenon with oat cell carcinoma, adenocarcinoma, and squamous cell carcinoma (27; 04; 52), with rare reports to include benign ovarian teratoma and esthesioneuroblastoma (32; 108). Older age and encephalopathy are associated with a paraneoplastic etiology of opsoclonus-myoclonus syndrome (05). Less commonly, it may be caused by lesions of the pons, cerebellum, or thalamus in the context of multiple sclerosis, stroke, or degenerative diseases such as Friedrich ataxia, LaFora body disease, and Hallervorden-Spatz disease (44). As such, opsoclonus-myoclonus syndrome has been noted in patients with locked-in syndrome from lesions in the ventral pons, which can inhibit their already limited ability to communicate. It is postulated that wider pontine damage to the mediodorsal pons may facilitate the development of opsoclonus-myoclonus syndrome (70). Opsoclonus caused by drugs or metabolic abnormalities is typically associated with impairment of consciousness, although intranasal cocaine (98) and chlordecone (the insecticide Kepone) cause opsoclonus-myoclonus in ambulatory patients (61).

Opsoclonus-myoclonus syndrome is most likely an autoimmune disorder involving the central nervous system (75). There may be immunologic cross-reactivity between neuroblastoma cells and selected neurons, with production of antineuronal antibodies. Alternatively, an infecting virus, through molecular mimicry, may stimulate the production of autoantibodies. Some infectious agents may effect this change through T cells, whereas others (like Epstein-Barr virus) may directly stimulate B cells to produce autoantibodies. Several antibodies have been identified in adult patients with opsoclonus-myoclonus syndrome (anti-Ri, anti-Yo, anti-Hu, anti-CAR, anti-neurofilament protein), but none of these antibodies are specific to opsoclonus-myoclonus syndrome (09). Autoantibodies to glutamate receptor delta 2 (GluD2) are common in pediatric patients with opsoclonus-myoclonus syndrome, although pathogenicity has yet to be established (11). A clinical case of anti-NMDA receptor encephalitis with associated opsoclonus-myoclonus found no other specific antibodies aside from the NMDA receptor antibody, suggesting a possible a role (56). Though a uniform autoantibody has not been found, studies have discovered an expansion in CD19+ B-cells in the CSF of patients with opsoclonus-myoclonus syndrome when compared to controls. This is without a concomitant increase in the percentage of CD19+ B cells or CD5+ B cells in the circulation. In addition, it was found that CSF expansion of both B-cell subsets increased with disease severity and decreased with disease duration. Although immunophenotyping of CSF lymphocytes is not currently readily available, the expansion of B-cells in CSF may represent a potential biomarker for disease activity as well as recurrence of symptoms (90).

Nevertheless, an immunologic mechanism is supported by the response of motor symptoms to adrenocorticotrophic hormone (ACTH), which increases T suppressor cells and natural killer cells and decreases antibody synthesis in B cells (74). Immunohistochemical studies have shown that children with opsoclonus-myoclonus syndrome produce IgM and IgG antibodies that bind to the cytoplasm of cerebellar Purkinje cells, whereas Western blot analysis has shown binding to several neural proteins, including a subunit of neurofilament (24). In addition, prominent peritumor lymphoid infiltrates have been identified in children with opsoclonus-myoclonus syndrome, which suggest a T cell dependent response to tumor-associated antigens and subsequent B cell activation with antibody production (59). Studies have also identified Nova-1, a protein expressed in neurons and in tumors, which binds in a sequence-specific manner to nuclear RNA in subcortical neurons. Nova-1 appears to be the target antigen in this paraneoplastic disorder. Antibodies produced in paraneoplastic opsoclonus-myoclonus inhibit the normal interaction between Nova-1 and nRNA (18; 17), presumably leading to neurologic dysfunction, specifically by interfering with the expression of the glycine receptor pathway. However, not all patients with opsoclonus-myoclonus syndrome exhibit the anti-Ri antibody that reacts with Nova-1, again illustrating the heterogeneity of disease markers (51). Also, supporting an immunologic mechanism is an increased prevalence of autoimmune disease in first-degree relatives of children with opsoclonus-myoclonus (97).

Although the anatomic substrate of opsoclonus, myoclonus, and ataxia has been difficult to localize, SPECT has shown increased perfusion in the cerebellar vermis during the acute phase of postinfectious opsoclonus-myoclonus (66). Other studies reflect dysfunction in the paramedian pontine reticular formation.

MR imaging with T1, DWI, and SPECT has revealed cerebellar grey matter reduction of the vermis and flocculonodular lobe as well as increased mean diffusivity of middle cerebellar tracks, implying decreased axonal integrity (03). Functional imaging with [18F]-FDG-PET has demonstrated reversible hyperactivity of the ocular muscles and vestibulo- and spinocerebellum that correlated with degree of clinical symptoms (63). It is postulated that an imbalance occurs between omnipause neurons that fire tonically until saccadic eye movements are made, and burst neurons that control oculomotor nerve function (91). The region of dysfunction extends from the locus coeruleus and the inferior olivary nucleus, involving serotonergic neurons of the raphe nuclei and olivary connections with the cerebellum. Abnormalities of cerebral function on examinations with EEG, VEP, PET, and SEP in children, however, argue for a degree of involvement of the cerebrum (95; 63).

Although brain biopsy is not necessary to diagnose or treat opsoclonus-myoclonus syndrome, a few biopsy and autopsy studies have demonstrated gliosis, loss of Purkinje cells, and occasional loss of granular cells in the cerebellum (26; 44; 107).

Diagnostic workup

	• Neuroimaging of the brain can exclude posterior fossa masses.
	• Careful screening for extracranial neuroblastoma can include whole body MRI or metaiodobenzylguanidine scanning.
	• Twenty-four-hour urine collection for vanillylmandelic acid and metanephrine can also be utilized to screen for neural crest tumors.

CT or MR imaging of the brain is necessary to exclude posterior fossa tumor as the cause of ataxia. In opsoclonus-myoclonus syndrome, these studies may appear normal or show abnormal signal in the cerebellar vermis (107). In addition, careful screening for extracranial neuroblastoma is essential. Whole body MR imaging from the neck to the pelvis has become more standard in this evaluation (92). Screening can also be effectively accomplished, or can follow-up inconclusive whole body MRI, with metaiodobenzylguanidine, which is a norepinephrine analog with 90% to 95% sensitivity and specificity for detection of neuroblastoma. Radiolabeled 123I or 131I metaiodobenzylguanidine scanning may permits tumor localization prior to directed CT or MR imaging for precise anatomic definition (67).

Lumbar puncture is appropriate to rule out meningitis; however, cerebrospinal fluid often shows only plasmacytosis. Furthermore, CSF pleocytosis may be seen when neural crest tumors are the cause of opsoclonus. Serum IgG is commonly increased. CSF oligoclonal bands are seen in a third of patients (and in over 50% in severe cases) and reflects local B-cell responses (76). Both serum and CSF should be examined for possible causative agents to include those known to be associated with opsoclonus-myoclonus and based on clinical suspicion.

Evaluation should include 24-hour urine collection for vanillylmandelic acid and metanephrine. However, measurements of urinary catecholamine metabolites may be normal in children with small neural crest tumors (61). Values of urinary vanillylmandelic acid, HVA, and noradrenaline are higher in patients whose tumors have a single N-myc DNA sequence (64), suggesting a better outcome for children with elevated catecholamine metabolites. Even if the initial workup is negative for neuroblastoma, periodic surveillance for neural crest tumors should be performed, especially in the absence of history to suggest a postinfectious etiology. Annual metaiodobenzylguanidine scanning may be more cost effective than whole-body CT or MRI.

Management

	• The most commonly used medications for treatment of opsoclonus-myoclonus are ACTH, corticosteroids, IVIg, and rituximab.
	• Increasing evidence is supportive of treatment with rituximab, a monoclonal anti-B cell antibody, especially as a part of multimodal therapy.
	• Peripherally administered rituximab lowers CSF expansion of B-cells, which has been shown to be a correlated marker of disease severity in opsoclonus-myoclonus.

Although the optimal treatment has not been established, the most commonly used medications for treatment of opsoclonus-myoclonus are ACTH, corticosteroids, IVIg, and rituximab. Short-term treatment with ACTH reduces symptoms in 80% to 90% of children with opsoclonus-myoclonus syndrome (74). Variability exists in the effective dose of ACTH, however. Some protocols begin with Acthar gel at 40 to 60 IU per day, given in divided IM injections. Clinical improvement occurs within days or weeks. Because patients may develop tolerance, ACTH therapy is often tapered by four months. However, symptoms commonly recur, and ACTH may have to be restarted or increased (40). Hypertension, hyperglycemia, and irritability are side effects of ACTH treatment that may limit duration of therapy, although some physicians use low-dose, alternate-day ACTH for extended periods.

Prednisone is used almost as often as ACTH but is usually less effective (40; 94). Thus, intravenous methylprednisolone at a dosing of 30 mg/kg/day (maximum of 1 gram/day) for 3 to 5 days, is often used before bridging to oral prednisone or prednisolone. Reports highlight some success, though, using high-dose pulse dexamethasone therapy (93; 31).

IVIg is occasionally used as an alternative to ACTH, or after ineffectiveness of ACTH or steroids (103; 69; 71). It may be administered over four hours, with slower rates of infusion for children experiencing hypotension or tremulousness. Anaphylaxis is a potential risk that can be minimized by using a formulation with less IgA and by pretreating with antihistamines.

Increasing evidence is supportive of early treatment with rituximab, whether as the initial treatment or as a quickly escalated treatment when there is an insufficient response to another treatment (92). Rituximab is a monoclonal anti-B cell antibody (88; 85; 19; 58), which when peripherally administered, lowers CSF expansion of B-cells and has been shown to be a correlated marker of disease severity in opsoclonus-myoclonus (90; 85). In a study of children with opsoclonus-myoclonus syndrome, Pranzatelli and colleagues treated 16 patients with rituximab as adjunctive therapy to ACTH, IVIg, or both (85). They found that at the six-month follow-up, their patients had lower motor severity scores and lower rage scores. Patients also had reduced nighttime awakening, opsoclonus, myoclonus, drooling, and ataxia. The dosing of rituximab used in this study was an IV infusion once weekly for four consecutive weeks at a dose of 375 mg/m2 of body surface area. A possible trend of decreasing effectiveness using this dosing regimen in children, as age and weight increase, has been suggested. The study’s findings of relative decrease in clinical responsiveness and correlating lower blood serum concentrations suggested a need for weight-based dosing of the medication in older children (89). However, this must be balanced against the potential side effects of hypogammaglobulinemia and B lymphopenia, with evidence showing reduced dosing rituximab in combination immunotherapy may be most prudent; however, long-term prospective research is needed to determine optimal dosing (83).

Immunologically, rituximab results in a correlating decrease in CSF B-cell expansion, which is sustained over 12 to 18 months despite repopulation in the blood (87). Oligoclonal bands also decrease by a mean band count of 80% with treatment and may be another possible method to monitor treatment (76). Other possible biomarkers that have been identified include cerebrospinal fluid B-cell activating factor (BAFF) and B cell attractant 1 (CXCL13) (79; 80). When using rituximab, however, close monitoring for adverse complications is needed as large multicenter retrospective data regarding its use in a heterogenous population of a pediatric autoimmune and inflammatory central nervous system disease found infusion adverse events in 12.5% and infectious adverse events in 7.6% (25).

When used in combination with either ACTH or IVIg, rituximab has also been reported to be safely used and more effective than ACTH or IVIg alone (84). In a study with prospectively obtained data, multimodal treatment (for which six different treatment groups with differing combinations of treatment were studied) was more effective than corticotrophin or IVIg alone (105). Data have similarly demonstrated improved outcomes of adaptive behavior, cognition, and motor scores with aggressive combination immunotherapy with either ACTH or bolus corticosteroid, IVIg, and either rituximab or cyclophosphamide (62).

The combination of pulse dexamethasone, intravenous immunoglobulin (IVIg), and rituximab combination immunotherapy (DEXIR-CI) has been reviewed retrospectively and has also shown clinical efficacy along with lowered B-cell frequencies in the cerebrospinal fluid and blood (77). This combination may be a potential treatment option for less severely affected patients, as the effectiveness of ACTH-based combination immunotherapy is well established (81).

International consensus guidelines outline two main broad treatment strategies: an “upfront” or an “escalating” strategy (92). In the upfront strategy, steroids, IVIg/or plasmapheresis, and cyclophosphamide/or rituximab are utilized in a combined therapy. In the escalating strategy, steroid therapy is initiated, with escalating therapies to include IVIg or plasmapheresis, and then if inadequate response, cyclophosphamide or rituximab. An international pediatric-onset opsoclonus-myoclonus ataxia syndrome registry has been organized, in part to best define optimal treatment. The primary objectives of the registry are to understand disease course, prognostic factors, and treatment efficacy, and then secondly, to create a registry of biological material and diagnostic imaging with clinical correlates (48).

Propranolol and primidone are ineffective. Rarely, azathioprine or valproate semisodium has been used for chronic treatment. The efficacious use of high-dose clonazepam has been reported (07). Plasmapheresis has been occasionally effective, and studies indicate that plasma exchange through a protein A column, which binds immune complexes and the Fc portion of IgG molecules, may abolish symptoms of opsoclonus and myoclonus (20; 65; 111). Mycophenolate mofetil, an immunomodulatory agent that inhibits B- and T-lymphocyte proliferation, has not shown a lasting effect on prevention of CSF B-cell expansion in children (86). Institution of gabapentin as therapy was seen as efficacious in symptomatic resolution when used in a small adult population affected by a causative structural lesion (70).

There is currently no consensus on the best approach to long-term treatment. In conjunction with medical treatment, early and sustained rehabilitation is also important to facilitate functional recovery and to moderate the impact of motor or cognitive deficits. Finally, as treatment with immunomodulation can disrupt childhood vaccination schedules, thoughtful consideration of catch-up vaccination should accompany the end of immunomodulatory therapy in opsoclonus-myoclonus syndrome to balance the risk of preventable illness with potential issues of opsoclonus-myoclonus syndrome reactivation and the ability of the patient to mount an appropriate response to vaccination (92).

Media

References

01: Alburaiky S, Dale RC, Crow YJ, et al. Opsoclonus-myoclonus in Aicardi-Goutieres syndrome. Dev Med Child Neurol 2021;63(12):1483-6. PMID 34155623
02: Altman AJ, Baehner RL. Favorable prognosis for survival in children with coincident opso-myoclonus and neuroblastoma. Cancer 1976;37:846-52. PMID 1253109
03: Anand G, Bridge H, Rackstraw P, et al. Cerebellar and cortical abnormalities in paediatric opsoclonus-myoclonus syndrome. Dev Med Child Neurol 2015;57(3):265-72. PMID 25290446
04: Anderson NE, Budde-Steffen C, Rosenblum MK, et al. Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine 1988;67:100-9. PMID 3352511
05: Armangue T, Sabater L, Torres-Vega E, et al. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol 2016;73(4):417-24. PMID 26856612
06: Ayarza A, Parisi V, Altclas J, et al. Opsoclonus-myoclonus-ataxia syndrome and HIV seroconversion. J Neurol 2009;256(6):1024-5. PMID 19252789
07: Bartos A. Effective high-dose clonazepam treatment in two patients with opsoclonus and myoclonus: GABAergic hypothesis. Eur Neurol 2006;56(4):240-2. PMID 17057386
08: Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus syndrome. Brain 2001;124:437-43. PMID 24565194
09: Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NK, Dalmau J. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003;53(3):347-53. PMID 12601702
10: Berg BO, Ablin AR, Wang W, Skoglund R. Encephalopathy associated with occult neuroblastoma. J Neurosurg 1974;41:567-72. PMID 4423363
11: Berridge G, Menassa DA, Moloney T, et al. Glutamate receptor delta-2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome. Neurology 2018;91(8):e714-23. PMID 30045961
12: Bill AH. The regression of neuroblastoma. J Pediatr Surg 1968;3:103-6. PMID 5655554
13: Blaes F, Pike MG, Lang B. Autoantibodies in childhood opsoclonus-myoclonus syndrome. J Neuroimmunol 2008;201-202:221-6. PMID 18687475
14: Boltshauser E, Deonna T, Hirt HR. Myoclonic encephalopathy of infants or "dancing eyes syndrome.” Report of 7 cases with long-term follow-up and review of the literature (cases with and without neuroblastoma). Helv Paediatr Acta 1979;34:119-33. PMID 222713
15: Bray PF, Ziter FA, Lahey ME, Myers CG. The coincidence of neuroblastoma and acute cerebellar encephalopathy. J Pediatr 1969;75:983-90. PMID 5352841
16: Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. Pediatrics 2011;128(2):e388-94. PMID 21788225
17: Buckanovich RJ, Darnell RB. The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo. Mol Cell Biol 1997;17:3194-201. PMID 9154818
18: Buckanovich RJ, Yang YY, Darnell RB. The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci 1996;16:1114-22. PMID 8558240
19: Burke MJ, Cohn SL. Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. Pediatr Blood Cancer 2008;50(3):679-80. PMID 16900484
20: Cher LM, Hockberg FH, Teruya J, et al. Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorption. Cancer 1995;75:1678-83. PMID 8826927
21: Chiba S, Motoya H, Shinoda M, Nakao T. Myoclonic encephalopathy of infants: a report of two cases of dancing eyes syndrome. Dev Med Child Neurol 1970;12:767-71. PMID 5490315
22: Christoff N. Myoclonic encephalopathy of infants: a report of two cases and observations on related disorders. Arch Neurol 1969;21:229-34. PMID 4308397
23: Cohn SL, Salwen H, Herst CV, et al. Single copies of the N-myc oncogene in neuroblastomas from children presenting with the syndrome of opsoclonus-myoclonus. Cancer 1988;62:723-6. PMID 3395955
24: Connolly AM, Pestronk A, Mehta S, Pranzatelli MR, Noetzel MJ. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. J Pediatr 1997;130:878-84. PMID 9202608
25: Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 2014;83:142-50. PMID 24920861
26: Digre KB. Opsoclonus in adults: report of three cases and review of literature. Arch Neurol 1986;43:1165-75. PMID 3535750
27: Dropcho E, Payne R. Paraneoplastic opsoclonus-myoclonus. Association with medullary thyroid carcinoma and review of the literature. Arch Neurol 1986;43:410-5. PMID 3954625
28: Dyken P, Kolar O. Dancing eyes, dancing feet: infantile polymyoclonus. Brain 1968;91:305-20. PMID 5721932
29: Emamikhah M, Babadi M, Mehrabani M, et al. Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of the literature. J Neurovirol 2021;27(1):26-34. PMID 33492608
30: Ertekin V, Tan H. Opsoclonus-myoclonus syndrome attributable to hepatitis C infection. Pediatr Neurol 2010;42(2):441-2. PMID 20472199
31: Ertle F, Behnisch W, Al Mulla NA, et al. Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses. Pediatr Blood Cancer 2008;50(3):683-7. PMID 17226843
32: Fitzpatrick AS, Gray OM, McConville J, McDonnell GV. Opsoclonus-myoclonus syndrome associated with benign ovarian teratoma. Neurology 2008;70(15):1292-3. PMID 18391162
33: Flabeau O, Meissner W, Foubert-Samier A, Guehl D, Desbordes P, Tison F. Opsoclonus myoclonus syndrome in the context of Salmonellosis. Mov Disord 2009;24(15):2306-8. PMID 19845009
34: Glaser JS. Neurophthalmology. Philadelphia: JB Lippincott, 1990:349.
35: Green D, Lim M, Lang B, Pohl K, Turk J. Sensory processing difficulties in opsoclonus-myoclonus syndrome: a pilot project of presentation. J Child Neurol 2016;31(8):965-70. PMID 26994071
36: Gurkas E, Gucuyener K, Yilmaz U, Havali C, Demir E. Opsoclonus-myoclonus syndrome following rotavirus gastroenteritis. Pediatr Int 2014;56(6):e86-7. PMID 25521990
37: Gwinn KA, Caviness JN. Electrophysiological observations in idiopathic opsoclonus-myoclonus syndrome. Mov Disord 1997;12:438-42. PMID 9159744
38: Haden SV, McShane MA, Holt CM. Opsoclonus myoclonus: a non-epileptic movement disorder that may present as status epilepticus. Arch Dis Child 2009;94(11):897-9. PMID 19847000
39: Hainline L, Turkel J, Abramov I, Lemerise E, Harris CM. Characteristics of saccades in human infants. Vision Res 1984;24:1771-80. PMID 6534000
40: Hammer MS, Larsen MB, Stack CV. Outcome of children with opsoclonus-myoclonus regardless of etiology. Pediatr Neurol 1995;13:21-4. PMID 7575843
41: Hoyt CS. Neonatal opsoclonus. J Pediatr Ophthalmol 1977;14:274-7. PMID 925840
42: Hoyt CS, Mousel DK, Weber AA. Transient supranuclear disturbances of gaze in healthy neonates. Am J Ophthalmol 1980;89:708-13. PMID 7377270
43: Huber BM, Strozzi S, Steinlin M, Aebi C, Fluri S. Mycoplasma pneumoniae associated opsoclonus-myoclonus syndrome in three cases. Eur J Pediatr 2010;169(4):441-5. PMID 19774394
44: Hunter S, Kooistra C. Neuropathologic findings in idiopathic opsoclonus and myoclonus. J Clin Neuro Ophthalmol 1986;6:236-41. PMID 2947929
45: Ichiba N, Miyake Y, Sato K, Oda M, Kimoto H. Mumps-induced opsoclonus-myoclonus and ataxia. Pediatr Neurol 1988;4:224-7. PMID 3242524
46: Jaffe N. Neuroblastoma: review of the literature and an examination of factors contributing to its enigmatic character. Cancer Treat Rev 1976;3:61-82. PMID 782702
47: Jones CE, Smyth DP, Faust SN. Opsoclonus-myoclonus syndrome associated with group a streptococcal infection. Pediatr Infect Dis J 2007;26(4):358-9. PMID 17414405
48: Kerr LM, Ryan ME, Lim M, et al. An international pediatric-onset opsoclonus-myoclonus ataxia syndrome registry and clinical research network: development, progress, and vision. Pediatr Neurol 2023;148:145-7. PMID 37716108
49: Khosla JS, Edelman MJ, Kennedy N, Reich SG. West Nile virus presenting as opsoclonus-myoclonus cerebellar ataxia. Neurology 2005;64(6):1095. PMID 15781844
50: Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry 1962;25:271-9. PMID 21610907
51: Kirsten A, Beck S, Kaps M, et al. New autoantibodies in pediatric opsoclonus-myoclonus syndrome. Ann NY Acad Sci 2007;1110:256-260. PMID 17911440
52: Klaas JP, Ahlskog JE, Pittock SJ, et al. Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol 2012;69(12):1598-607. PMID 22986354
53: Klein A, Schmitt B, Boltshauser E. Long-term outcome of ten children with opsoclonus-myoclonus syndrome. Eur J Pediatr 2007;166(4):359-63. PMID 17089089
54: Klingelhoefer L, Misbahuddin A, Jawad T, et al. Vanishing white matter disease presenting as opsoclonus myoclonus syndrome in childhood--a case report and review of the literature. Pediatr Neurol 2014;51:157-64. PMID 24938145
55: Kuban KC, Ephros MA, Freeman RL, Laffell LB, Bresnan MJ. Syndrome of opsoclonus-myoclonus caused by Coxsackie B3 infection. Ann Neurol 1983;13:69-71. PMID 6299176
56: Kurian M, Lalive PH, Dalmau JO, Horvath J. Opsoclonus-myoclonus syndrome in anti N-methyl-D-aspartate receptor encephalitis. Arch Neurol 2010;67(1):118-21. PMID 20065141
57: Larbrisseau A, Geoffroy G, Lasalle R. Association du'un neuroblastome avec un syndrome de polymyoclonie-opsoclonie. Union Med Can 1973;102:1691-4. PMID 4792859
58: Leen WG, Weemaes CM, Verbeek MM, Willemsen MA, Rotteveel JJ. Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome. Pediatr Neurol 2008;39(3):213-7. PMID 18725071
59: Matthay KK, Blaes F, Hero B, et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett 2005;228(1-2):275-82. PMID 15922508
60: McCarthy JE, Filiano J. Opsoclonus myoclonus after human papilloma virus vaccine in a pediatric patient. Parkinsonism Relat Disord 2009;15(10):792-4. PMID 19447066
61: Mitchell WG, Snodgrass SR. Opsoclonus-ataxia due to childhood neural crest tumors: a chronic neurologic syndrome. J Child Neurol 1990;5:153-8. PMID 2345282
62: Mitchell WG, Wooten AA, O'Neil SH, Rodriguez JG, Cruz RE, Wittern R. Effect of increased immunosuppression on developmental outcome of opsoclonus myoclonus syndrome (OMS). J Child Neurol 2015;30(8):976-82. PMID 25342308
63: Mustafa M, Levin J, Schöberl F, Rominger A. Postinfectious opsoclonus-myoclonus syndrome in a 41-year-old patient-visualizing hyperactivation in deep cerebellar nuclei by cerebral [(18) F]-FDG- PET. J Neuroimaging 2015;25(4):683-5. PMID 25510336
64: Nakagawara A, Ikeda K, Higashi K, Sasazuki T. Inverse correlation between N-myc amplification and catecholamine metabolism in children with advanced neuroblastoma. Surgery 1990;107:43-50. PMID 2404349
65: Nitschke M, Hochberg F, Dropcho E. Improvement of paraneoplastic opsoclonus-myoclonus after protein A column therapy [letter]. N Engl J Med 1995;332:192. PMID 7800020
66: Oguro K, Kobayashi J, Aiba H, Hojo H. Opsoclonus-myoclonus syndrome with abnormal single photon emission computed tomography imaging. Pediatr Neurol 1997;16:334-6. PMID 9258970
67: Parisi MT, Hattner RS, Matthay KK, Berg BO, Sandler ED. Optimized diagnostic strategy for neuroblastoma in opsoclonus-myoclonus. J Nucl Med 1993;34:1922-6. PMID 8229235
68: Peter L, Jung J, Tilikete C, Ryvlin P, Mauguiere F. Opsoclonus-myoclonus as a manifestation of Lyme disease. J Neurol Neurosurg Psychiatry 2006;77(9):1090-1. PMID 16914760
69: Petruzzi MJ, De Alarcon PA. Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G. J Pediatr 1995;127:328-9. PMID 7636667
70: Pistoia F, Conson M, Sara M. Opsoclonus-myoclonus syndrome in patients with locked-in syndrome: a theraputic porthole with gabapentin. Mayo Clin Proc 2010;85(6):527-31. PMID 20511483
71: Pless M, Ronthal M. Treatment of opsoclonus-myoclonus with high-dose intravenous immunoglobulin. Neurology 1996;46(2):583-4. PMID 8614543
72: Pochedly C, Strauss L. Histogenesis and pathology of neuroblastoma. In: Pochedly C, editor. Neuroblastoma. Acton, Massachusetts: Publishing Sciences, 1976:155-79.
73: Pranzatelli MR. Neurobiology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 1992;15:186-228. PMID 1394242
74: Pranzatelli MR. On the molecular mechanism of adrenocorticotropic hormone in the CNS: neurotransmitters and receptors. Exp Neurol 1994;125:1-20. PMID 7905835
75: Pranzatelli MR. The immunopharmacology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 1996;19:1-47. PMID 8867515
76: Pranzatelli MR, Slev PR, Tate ED, Travelstead AL, Colliver JA, Joseph SA. Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonus. Pediatr Neurol 2011;45(1):27-33. PMID 21723456
77: Pranzatelli MR, Tate ED. Dexamethasone, intravenous immunoglobulin, and rituximab combination immunotherapy for pediatric opsoclonus-myoclonus syndrome. Pediatr Neurol 2017;73:48-56. PMID 28651977
78: Pranzatelli MR, Tate ED, Dukart WS, Flint MJ, Hoffman MT, Oksa AE. Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. J Pediatr 2005a;147(3):372-8. PMID 16182678
79: Pranzatelli MR, Tate ED, McGee NR, et al. Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS. J Neuroimmunol 2012;243(1-2):81-8. PMID 22264765
80: Pranzatelli MR, Tate ED, McGee NR, et al. BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy. J Neuroinflammation 2013;10:10. PMID 23324534
81: Pranzatelli MR, Tate ED, McGee NR. Demographic, clinical and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study. Front Neurol 2017;8:468. PMID 28959231
82: Pranzatelli MR, Tate ED, McGee NR. Multifactorial analysis of opsoclonus-myoclonus syndrome etiology (“tumor vs. “no tumor”) in a cohort of 356 US children. Pediatr Blood Cancer 2018a;65(8):e27097. PMID 29727049
83: Pranzatelli MR, Tate ED, McGee NR, MacArthur CA. Evaluation of responsiveness to reduced-dose rituximab in corticotropin/intravenous immunoglobulin/rituximab combination immunotherapy for opsoclonus-myoclonus syndrome. Pediatr Neurol 2018b;85:71-5. PMID 30197220
84: Pranzatelli MR, Tate ED, Swan JA, et al. B cell depletion therapy for new-onset opsoclonus-myoclonus. Mov Disord 2010b;25(2):238-42. PMID 20063398
85: Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006;28(9):585-93. PMID 17006265
86: Pranzatelli MR, Tate ED, Travelstead AL, et al. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil. J Child Neurol 2009;24(3):316-22. PMID 19258290
87: Pranzatelli MR, Tate ED, Travelstead AL, Colliver JA. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus. J Clin Immunol 2010a;30(1):106-13. PMID 19838774
88: Pranzatelli MR, Tate ED, Travelstead AL, Longee D. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome. Pediatrics 2005b;115(1):e115-9. PMID 15601813
89: Pranzatelli MR, Tate ED, Verhulst SJ, et al. Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndromes. J Pediatr Hematol Oncol 2010c;32(5):e167-72. PMID 20606544
90: Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Mov Disord 2004;19(7):770-7. PMID 15254934
91: Ridley A, Kennard C, Scholtz CL, Buttner-Ennever JA, Summers B, Turnbull A. Omnipause neurons in two cases of opsoclonus associated with oat cell carcinoma of the lung. Brain 1987;110:1699-709. PMID 2827840
92: Rossor T, Yeh A, Khakoo Y, et al. Diagnosis and management of opsoclonus-myoclonus-ataxia syndrome in children. Neurol Neuroimmunol Neuroinflamm 2022;9(3):e1153. PMID 35260471
93: Rostasy K, Wilken B, Baumann M, et al. High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome. Neuropediatrics 2006;37(5):291-5. PMID 17236108
94: Russo C, Cohn SL, Petruzzi MJ, DeAlarcon PA. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997;28:284-8. PMID 9078325
95: Sakuma H, Shimizu Y, Saito Y, et al. Electrophysiological evidence of cerebral dysfunction in childhood opsoclonus-myoclonus syndrome. Mov Disord 2010;25(7):940-5. PMID 20461811
96: Sandok BA, Kranz H. Opsoclonus as the initial manifestation of occult neuroblastoma. Arch Ophthalmol 1971;86:235-6. PMID 4328390
97: Santoro JD, Kerr LM, Codden R, et al. Increased prevalence of familial autoimmune disease in children with opsoclonus-myoclonus syndrome. Neurol Neuroimmunol Neuroinflamm 2021;8:e1079. PMID 34475249
98: Scharf D. Opsoclonus-myoclonus following the intranasal usage of cocaine (letter). J Neurol Neurosurg Psychiatry 1989;52:1447-8. PMID 2614455
99: Senelick RC, Bray PF, Lahey E, Van Dyk HJ, Johnson DG. Neuroblastoma and myoclonic encephalopathy: two cases and a review of the literature. J Pediatr Surg 1973;8:623-32. PMID 4752998
100: Shah PB, Desai SD. Opsoclonus myoclonus ataxia syndrome (OMAS) in the setting of COVID-19 infection. Neurology 2021;96(1):33. PMID 33004603
101: Sheridan A, Kapur K, Pinard F, et al. IQ predictors in pediatric opsoclonus myoclonus syndrome: a large international cohort study. Dev Med Child Neurol 2020;62(12):1444-9. PMID 32696984
102: Solomon GE, Chutorian AM. Opsoclonus and occult neuroblastoma. N Engl J Med 1968;279:475-7. PMID 5663722
103: Sugie H, Sugie Y, Akimoto H, Endo K. High-dose human immunoglobulin in a case with infantile opsoclonus polymyoclonia syndrome. Acta Pediatrica 1992;81:371-2. PMID 1606405
104: Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs 2005;22:8-19. PMID 15574722
105: Tate ED, Pranzatelli MR, Verhulst SJ, et al. Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome. J Child Neurol 2012;27(7):875-84. PMID 22378659
106: Telander RL, Smithson WA, Grover RV. Clinical outcome in children with acute cerebellar encephalopathy and neuroblastoma. J Pediatr Surgery 1989;24:11-4. PMID 2723981
107: Tuchman RF, Alvarez LA, Kantrowitz AB, Moser FG, Llena J, Moshe SL. Opsoclonus-myoclonus syndrome: correlation of radiographic and pathological observations. Neuroradiology 1989;31:250-2. PMID 2779775
108: Van Diest D, De Raeve H, Claes J, Parizel PM, De Ridder D, Cras P. Paraneoplastic opsoclonus-myoclonus-ataxia (OMA) syndrome in an adult patient with esthesioneuroblastoma. J Neurol 2008;255(4):594-6. PMID 18231703
109: Woods WG, Lemieux B, Tuchman M. Neuroblastoma represents distinct clinical-biologic entities: a review and perspective from the Quebec neuroblastoma screening project. Pediatrics 1992;89:114-8. PMID 1727993
110: Woods WG, Tuchman M. Neuroblastoma: the case for screening infants in North America. Pediatrics 1987;79:869-73. PMID 3588142
111: Yiu VW, Kovithavongs T, McGonigle LF, Ferreira P. Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome. Pediatr Neurol 2001;24(1):72-4. PMID 11182286
112: Zaganas I, Prinianakis G, Xirouchaki N, Mavridis M. Opsoclonus-myoclonus syndrome associated with cytomegalovirus encephalitis. Neurology 2007;68(19):1636. PMID 17485656

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

David T Hsieh MD

Dr. Hsieh of the Uniformed Services University of the Health Sciences has no relevant financial relationships to disclose.
See Profile

Editor

Bernard L Maria MD

Dr. Maria of Thomas Jefferson University has no relevant financial relationships to disclose.
See Profile

Former Authors

David A Griesemer MD (original author), David Koury MD, E Brannon Morris III MD, Susan L Hobernicht MD, and Latanya D Agurs MD

Patient Profile

Age range of presentation: 1 months to 65+ years
Sex preponderance: female>male
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Unspecified extrapyramidal diseases and abnormal movement disorders: 333.90

Opsoclonus: 379.59
ICD-10: Myoclonus: G25.3

Extrapyramidal and movement disorder, unspecified: G25.9

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Opsoclonus-myoclonus

Associated Disorders

Acute cerebellar encephalopathy
Infantile myoclonic encephalopathy
Myoclonic encephalopathy
Neuroblastoma
Neural crest tumor

Differential Diagnosis

acute cerebellar ataxia
postinfectious cerebellar ataxia
posterior fossa tumor
other disorders causing brainstem dysfunction
healthy neonates with immature oculomotor control
- epileptic myoclonus
- refractory status epilepticus

Also Relevant

Childhood movement disorders
Early myoclonic encephalopathy
Gabapentin
Myoclonus
Paraneoplastic cerebellar degeneration
- Paraneoplastic opsoclonus myoclonus syndrome in adults
- Paraneoplastic syndromes

Opsoclonus-myoclonus …

Opsoclonus-myoclonus

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Autoantibodies: mechanism and testing

NF2-related schwannomatosis

Prion diseases

Rabies

Malaria

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

Opsoclonus-myoclonus

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Autoantibodies: mechanism and testing

NF2-related schwannomatosis

Prion diseases

Rabies

Malaria

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

This is an article preview.
Start a Free Account
to access the full version.